In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores the data and recommendations for HIV postexposure prophylaxis (PEP). Listen as she gives perspectives on: The CDC algorithm for evaluation and treatment of potential HIV exposures The CDC guideline preferred and alternative PEP antiretroviral therapy regimens Data for the use of the single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide for PEP Recommended laboratory monitoring with PEP The initiation of ...
May 26, 2022•25 min•Ep. 176
In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for choosing antiretroviral therapy (ART) for pediatric patients. Listen as she gives perspectives on: Department of Health and Human Services (DHHS) guideline recommendations for infants at risk for perinatal HIV transmission DHHS guideline–recommended ART regimens for children The ODYSSEY A and B studies evaluating dolutegravir-based ART in children and adolescents Data for the use of the fixed-dose...
May 25, 2022•21 min•Ep. 175
In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for transgender people with HIV (PWH). Listen as she gives perspectives on: Department of Health and Human Services (DHHS) guideline recommendations for transgender PWH Providing HIV care within a gender-affirmative care model, including discussion of strategies, barriers, and facilitators Gender-affirmative hormone therapy options Drug–drug interaction potential between gender-affirmative hormone the...
May 25, 2022•28 min•Ep. 174
In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses: Principles for antiviral agent use in nonhospitalized patients Preferred and alternative treatment options Treatment prioritization when there are logistical or supply constraints Outpatient remdesivir use PINETREE data (adult patients) CARAVAN data (pediatric patients) FDA approval and treatment candidacy Therapeutic updates Ivermectin and the TOGETHER study Monoclonal antibody use during current omicron era Presenter: Sharon R...
May 24, 2022•35 min•Ep. 173
In this episode, Dexter James Wiseman, MD, discusses immunology and RSV vaccine development for older adults, including: Need for a vaccine Economic burden of RSV Reasons for poor outcomes in older adults Investigational vaccines Presenter: Dexter James Wiseman, MD Clinical Research Fellow NHLI Imperial College Physician Respiratory Medicine Royal Brompton Hospital London, United Kingdom Review the downloadable slideset and the full program at: https://bit.ly/3ydC8Ri Hosted by Simplecast, an Ads...
May 05, 2022•14 min•Ep. 171
In this episode, Dexter James Wiseman, MD, discusses the epidemiology and risk factors for RSV in older adults, including: Overview Disease burden based on age Seasonality Impact in care facilities Effects of the COVID-19 pandemic Presenter: Dexter James Wiseman, MD Clinical Research Fellow NHLI Imperial College Physician Respiratory Medicine Royal Brompton Hospital London, United Kingdom Review the downloadable slideset and the full program at: https://bit.ly/3ydC8Ri Hosted by Simplecast, an Ad...
May 05, 2022•15 min•Ep. 168
In this episode, Dexter James Wiseman, MD, discusses the impact and diagnosis of RSV in older adults, including: Risk factors for poor outcomes RSV vs influenza outcomes RSV symptoms RSV diagnostics Presenter: Dexter James Wiseman, MD Clinical Research Fellow NHLI Imperial College Physician Respiratory Medicine Royal Brompton Hospital London, United Kingdom Review the downloadable slideset and the full program at: https://bit.ly/3ydC8Ri Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.c...
May 05, 2022•14 min•Ep. 170
In this episode, listen as Robert G. Gish, MD, discusses key information on comparing current HBV vaccine formulations, and learn the best immunization practices for routine vaccination, including in special situations. Presenter: Robert G. Gish, MD Professor of Medicine Loma Linda University Loma Linda, California Adjunct Professor of Medicine Nevada School of Medicine Las Vega, Nevada Clinical Professor University of Nevada Reno School of Medicine Reno, Nevada Clinical Professor University of ...
May 05, 2022•9 min•Ep. 166
In this episode, learn about the importance of identifying adults at risk for reduced hepatitis B virus (HBV) seroprotection and applying current HBV vaccine recommendations in special populations. Listen as Robert G. Gish, MD, discusses key information on the identification and evaluation of patients who have chronic health conditions and therefore may be at risk for nonresponse to available vaccines. Presenter: Robert G. Gish, MD Professor of Medicine Loma Linda University Loma Linda, Californ...
May 05, 2022•11 min•Ep. 169
In this episode, learn about the importance of hepatitis B virus (HBV) vaccination in adults. Listen as Robert G. Gish, MD, discusses key data on the burden and impact of HBV infection, and strategies to overcome barriers to HBV vaccination. Robert G. Gish, MD Professor of Medicine Loma Linda University Loma Linda, California Adjunct Professor of Medicine Nevada School of Medicine Las Vega, Nevada Clinical Professor University of Nevada Reno School of Medicine Reno, Nevada Clinical Professor Uni...
May 05, 2022•12 min•Ep. 167
Hepatitis delta virus (HDV) is the most severe form of viral hepatitis, yet many patients go undiagnosed. Increasing HDV awareness is an important step to correct this and ensure that at-risk patients receive screening and then treatment and monitoring following a positive test. Hear Grace LH Wong, MD, and Ming-Lung Yu, MD, PhD, discuss a call to action to increase healthcare professional and patient awareness of HDV. Presenters: Grace LH Wong, MD Professor Director , Medical Data Analytics Cent...
May 03, 2022•14 min•Ep. 159
In this episode, Norah Terrault, MD, MPH, and a patient who has been cured of hepatitis C virus (HCV) infection discuss the importance of universal HCV testing for all adults, as well as the ease of curative therapies and the benefits of living with improved liver function post cure. This insightful discussion underscores how perceptions around HCV transmission risks and lack of symptoms serve as barriers to adequate screening and diagnosis, preventing curative treatment for many people with und...
May 03, 2022•18 min•Ep. 165
In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss novel therapies for HIV prevention and treatment, including: Prevention Cabotegravir for pre-exposure prophylaxis (PrEP) with the latest results from the HPTN 083 and HPTN 084 studies Novel PrEP therapies in development, including islatravir and lenacapavir Initial therapy Lenacapavir for initial therapy with results from the CALIBRATE study Switch strategies Cabotegr...
May 02, 2022•49 min•Ep. 164
In this podcast, Dr Dominique Laurent Braun discusses his micro-elimination program, the Swiss HCVree trial, designed to prevent hepatitis C virus (HCV) transmission among HIV-positive men who have sex with men. The study employed a test-and-treat approach to eliminate HCV infection in this key target population and could be a model for other countries to eliminate HCV infection in certain populations. Presenter: Dominique Laurent Braun, MD Senior Staff Physician Division of Infectious Diseases ...
Apr 27, 2022•22 min•Ep. 163
Antiviral agents continue to be effective against different strains of SARS-CoV-2 when used early in the disease course. In this episode, learn about the role of antiviral agents in hospitalized and high-risk nonhospitalized patients with COVID-19 and in different age groups. Listen as David A. Wohl, MD, discusses when and how to use IV and oral antiviral agents including: Nirmatrelvir + ritonavir Remdesivir Molnupiravir Presenter: David A. Wohl, MD Professor of Medicine School of Medicine Site ...
Apr 25, 2022•23 min•Ep. 162
The place of monoclonal antibodies in COVID-19 is changing. In this episode, learn about their role in prophylaxis of patients who are at high risk of complications from acquiring COVID-19 or treatment of high-risk patients who have a mild to moderate COVID-19 infection. Listen as Gregory Huhn, MD, MPHTM, discusses when and how to use monoclonal antibodies including: Bebtelovimab Cilgavimab/tixagevimab Sotrovimab Presenter: Gregory Huhn, MD, MPHTM Associate Professor Department of Infectious Dis...
Apr 21, 2022•30 min•Ep. 161
In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and a patient with previous injection drug use who has been cured of HCV infection discuss critical barriers that are preventing more people with current or previous injection drug use from receiving appropriate HCV care. This insightful discussion underscores the negative effects of stigma toward people who inject drugs that exist in many clinical settings, the important role that socioeconomic factors such as transportation access and stable...
Apr 20, 2022•20 min•Ep. 160
In this episode, Renslow Sherer, MD, discusses what is known to date regarding long COVID, also known as postacute sequelae of COVID-19 infection, including: Possible causes and risk factors Signs and symptoms Clinical management Treatment options under consideration Role of vaccination Presenter: Renslow Sherer, MD Director , International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois Rev...
Apr 13, 2022•39 min•Ep. 158
In episode 7 of a series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss: Role of family history in risk of hepatocellular carcinoma (HCC) Surveillance for HCC Steps to take when diagnosed with HCC How to live a healthy life after HCC diagnosis and treatment Presenter : Ming-Lung Yu, MD, PhD Chair Professor Hepatobiliary Division Department of Internal Medicine and Hepatitis Center Kaohsiung Medical Univ...
Apr 12, 2022•14 min•Ep. 157
Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection. In this episode, Vikramjit Mukherjee, MD, discusses the role and timing of these treatment options, including: High-titer convalescent plasma Corticosteroids Interleukin-6 inhibitors (eg, tocilizumab) Janus kinase inhibitors (eg, baricitinib) Presenter: Vikramjit Mukherjee, MD Assistant Professor of Medicine Division of Pulmonary, Critical Care, &a...
Apr 07, 2022•15 min•Ep. 156
In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including: When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infections EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infections Considerations for the administr...
Apr 05, 2022•42 min•Ep. 155
In this episode, Heiner Wedemeyer, MD, discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV. Presenter: Heiner Wedemeyer, MD Professor and Chairman Department of Gastroenterology, Hepatology and Endocrinology Hannover Medical School Hannover, Germany Content based on an online CM...
Mar 30, 2022•25 min•Ep. 154
Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in rural settings, including facing up to stigma, getting access to experienced medical practitioners, and searching for information and peer support. Presenter: Paul Y. Kwo, MD Professor of Medicine Director of Hepatology Stanford University School of Medicine Palo Alto, California Content based on an o...
Mar 25, 2022•18 min•Ep. 153
In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including: Discussion of the PrEP gap and racial and gender disparities in PrEP access CDC, EACS, and WHO guidance on PrEP eligibility PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir Data from clinical trials on the ef...
Mar 25, 2022•32 min•Ep. 152
In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including: Discussion of the PrEP gap and racial and gender disparities in PrEP access CDC, EACS, and WHO guidance on PrEP eligibility PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir Data from phase III trials on the efficacy of FTC/TDF d...
Mar 24, 2022•39 min•Ep. 151
In this episode, Graham R. Foster, FRCP, PhD, and Paul Y. Kwo, MD, share lessons learned in the management of HCC and liver transplantation the COVID-19 era, including: • Global impact of HCC and strategies for maintaining HCC care in the COVID-19 era • Characteristics of liver transplant recipients in the COVID-19 era • Impact of COVID-19 pandemic period on liver transplant outcomes • Impact of liver transplant status on COVID-19 outcomes • Strategies for providing streamlined care for patients...
Mar 23, 2022•30 min•Ep. 150
In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP). - Listen as he gives his perspectives on: - The FDA approval of long-acting cabotegravir for PrEP - Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy - Considerations for long-acting cabotegravir as PrEP Dosing and administration Managing missed doses Discontinuation Delays in HIV diagnoses found in the HPTN 0...
Mar 21, 2022•13 min•Ep. 149
Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes: Assembly inhibitors (eg, lonafarnib) Entry inhibitors (eg, bulevirtide) Interferon lambda Nucleic acid polymers Small interfering...
Mar 16, 2022•21 min•Ep. 142
In this episode, Jeffrey Kwong, DNP, MPH, FAANP, FAAN, and Susan LeLacheur, DrPH, PA-C, AAHIVS, share insights on new HIV data from CROI 2022, including: Perinatal antiretroviral therapy exposure Investigational formulation of long-acting contraception combined with pre-exposure prophylaxis Monitoring with long-acting cabotegravir for pre-exposure prophylaxis Myocardial infarction risk by HIV status Presenters: Jeffrey Kwong, DNP, MPH, FAANP, FAAN Professor Division of Advanced Nursing Practice ...
Mar 16, 2022•18 min•Ep. 148
In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including: Epidemiology and burden of nosocomial bacterial pneumonia Patient-specific risk factors for MDR pathogens Improving outcomes with the use of antibiograms Recommended empiric therapy for clinically suspected VABP Antimicrobial resistance in HABP/VABP Algorithms for gram-negative organism antibiotic-susceptibility testing Using rapid diagnostic test...
Mar 15, 2022•1 hr 42 min•Ep. 146
